Case Reports
doi: 10.1016/j.jdcr.2016.07.006.
eCollection 2016 Jul.
Intralesional rituximab for cutaneous manifestations of systemic B-cell lymphoma
Affiliations
- PMID: 27570817
- PMCID: PMC4992004
- DOI: 10.1016/j.jdcr.2016.07.006
Item in Clipboard
Case Reports
Intralesional rituximab for cutaneous manifestations of systemic B-cell lymphoma
JAAD Case Rep.
.
No abstract available
Keywords: CBCL, cutaneous B-cell lymphoma; cutaneous B-cell lymphoma; cutaneous lymphoma treatment; intralesional rituximab.
Figures
A and B, Cutaneous lesions before intralesional rituximab. C and D, The result after the last treatment cycle.
Similar articles
-
Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.Br J Dermatol. 2006 Dec;155(6):1197-200. doi: 10.1111/j.1365-2133.2006.07523.x. Br J Dermatol. 2006. PMID: 17107389
-
Treatment of primary cutaneous B-cell lymphoma with rituximab.J Am Acad Dermatol. 2005 May;52(5):847-53. doi: 10.1016/j.jaad.2005.01.093. J Am Acad Dermatol. 2005. PMID: 15858476
-
Intralesional rituximab for cutaneous B-cell lymphoma.Br J Dermatol. 2001 Jun;144(6):1239-43. doi: 10.1046/j.1365-2133.2001.04241.x. Br J Dermatol. 2001. PMID: 11422050
-
Innovative Therapeutic Approaches in Primary Cutaneous B Cell Lymphoma.Front Oncol. 2020 Aug 7;10:1163. doi: 10.3389/fonc.2020.01163. eCollection 2020. Front Oncol. 2020. PMID: 32850331 Free PMC article. Review.
-
[Cutaneous follicular center B-cell lymphoma treated with intralesional rituximab].Actas Dermosifiliogr. 2008 May;99(4):291-6. Actas Dermosifiliogr. 2008. PMID: 18394405 Review. Spanish.
Cited by
-
Intralesional Agents in Dermatology: Pros and Cons.J Cutan Aesthet Surg. 2021 Jul-Sep;14(3):285-295. doi: 10.4103/JCAS.JCAS_109_20. J Cutan Aesthet Surg. 2021. PMID: 34908770 Free PMC article. Review.
-
Treatment of Indolent Cutaneous B-Cell Lymphoma with Intralesional or Intravenous Rituximab.Cancers (Basel). 2022 Sep 30;14(19):4787. doi: 10.3390/cancers14194787. Cancers (Basel). 2022. PMID: 36230709 Free PMC article.
References
-
- Gamo R., Calzado L., Pinedo F., Lopez-Estebaranz J.L. Cutaneous Follicular Center B-Cell lymphoma treated with intralesional Rituximab. Actas Dermosifiliogr. 2008;99:291–296. - PubMed
-
- Bolognia J, Jorizo J, Schaffer J, ed. Dermatology. Vol 2, 3rd edition. Philadelphia, PA: Elsevier Saunders; 2012
-
- Heinzerling L., Dummer R., Kempf W., Schmid M.H., Burg G. Intralesional Therapy with anti-CD20 monoclonal antibody Rituximab in primary cutaneous B-cell lymphoma. Arch Dermatol. 2000;136:374–378. - PubMed
-
- Penate Y., Hernandez-Machin B., Perez-Mendez L.I. Intralesional Rituximab in the treatment of indolent primary cutaneous B-cell lymphomas : an epidemiological observational multicenter study. Br J Dermatol. 2012;167:174–179. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources